Generic Medicine Info
May be taken with or without food.
Hypotension, mild to severe heart failure, acute recent MI; other conditions wherein sexual activity is inadvisable; recent stroke, uncontrolled arrhythmias and/or HTN, unstable angina, vision loss due to non-arteritic anterior ischaemic optic neuropathy (NAION). Severe hepatic impairment (Child-Pugh class C) when used for pulmonary arterial hypertension. Concomitant use of any form of organic nitrates, nitric oxide donors, and guanylate cyclase stimulators.
Special Precautions
Patient w/ retinitis pigmentosa, left ventricular outflow obstruction (aortic stenosis or hypertrophic obstructive cardiomyopathy), anatomical penile deformation, conditions which may be predisposed to priapism (e.g. sickle cell anaemia, multiple myeloma, leukemia); bleeding disorders, peptic ulcer disease, pulmonary veno-occlusive disease. Renal and hepatic impairment. Pregnancy and lactation. Monitoring Parameters Assess CV status prior to initiation of therapy. Monitor BP.
Adverse Reactions
Significant: Hypotension, TIA, anginal chest pain, palpitations, tachycardia, color discrimination impairment, vision loss/NAION, sudden decrease or loss of hearing, tinnitus, dizziness. Rarely, prolonged/painful erection or priapism. Nervous: Headache, dizziness, fatigue. Rarely, transient amnesia. CV: HTN, flushing, peripheral oedema. GI: Nausea, dyspepsia, abdominal pain, vomiting, diarrhoea, gastroenteritis, GERD. Resp: Nasopharyngitis, nasal congestion, dyspnoea, cough, epistaxis, resp tract infection. Haematologic: Haematuria. Musculoskeletal: Myalgia, back and limb pain, pain in extremities. Otic: Tinnitus. Ophthalmologic: Blurred vision, eye pain. Dermatologic: Rash. Immunologic: Hypersensitivity.
Potentially Fatal: Serious CV events (e.g. MI, stroke, sudden cardiac death, unstable angina pectoris, ventricular arrhythmia).
Drug Interactions
May enhance hypotensive effect of α1-adrenergic blockers, and other antihypertensive drugs (e.g. amlodipine, enalapril, metoprolol, bendrofluazide). Increased serum concentration w/ CYP3A4 inhibitors (e.g. azole antifungals, macrolides, HIV protease inhibitors, cimetidine). Decreased serum concentration w/ CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin, phenobarbital).
ATC Classification
G04BE08 - tadalafil ; Belongs to the class of drugs used in erectile dysfunction.
Disclaimer: This information is independently developed by CIMS based on tadalafil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in